Cargando…
Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
BACKGROUND: Mutations in the BRCA1, BRCA2 and PALB2 genes are well-established risk factors for the development of breast and/or ovarian cancer. The frequency and spectrum of mutations in these genes has not yet been examined in the population of Southern Poland. METHODS: We examined the entire codi...
Autores principales: | Wojcik, P., Jasiowka, M., Strycharz, E., Sobol, M., Hodorowicz-Zaniewska, D., Skotnicki, P., Byrski, T., Blecharz, P., Marczyk, E., Cedrych, I., Jakubowicz, J., Lubiński, J., Sopik, V., Narod, S., Pierzchalski, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739084/ https://www.ncbi.nlm.nih.gov/pubmed/26843898 http://dx.doi.org/10.1186/s13053-016-0046-5 |
Ejemplares similares
-
Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021) -
Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015) -
Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer
por: Szatkowski, Wiktor, et al.
Publicado: (2016) -
Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012) -
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)